{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:04:58Z","timestamp":1773288298792,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"s65","license":[{"start":{"date-parts":[[2002,4,19]],"date-time":"2002-04-19T00:00:00Z","timestamp":1019174400000},"content-version":"vor","delay-in-days":414,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p>Chronic idiopathic urticaria (CIU) is a common dermatologic disorder that may severely impair quality of life. Patients may suffer symptoms such as pruritus and disfigurement due to wheals for years or decades. Advances have been made in the last 10 years with the identification of an autoimmune pathogenesis in a significant proportion of patients. Despite this, treatment remains symptomatic, and antihistamines are the first choice of therapy once the diagnosis of CIU has been established. The goal of treatment is rapid, long\u2010lasting symptom relief, and currently available antihistamines fail to provide this in many cases. Desloratadine is a novel, potent H<jats:sub>1<\/jats:sub>\u2010receptor antagonist with additional inhibitory effects on inflammatory mediators such as cytokines and adhesion molecules. Newly published data on the efficacy and safety of desloratadine in CIU is highly encouraging, suggesting that the drug may improve symptom control above that currently available.<\/jats:p>","DOI":"10.1034\/j.1398-9995.2001.00104.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T01:47:47Z","timestamp":1047347267000},"page":"28-32","source":"Crossref","is-referenced-by-count":22,"title":["Desloratadine in the treatment of chronic idiopathic urticaria"],"prefix":"10.1034","volume":"56","author":[{"given":"J.","family":"Ring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1997.03890440085013","article-title":"The pathogenesis of chronic idiopathic urticaria","volume":"133","author":"Sabroe RA","year":"1997","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03246.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506293322608"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.00006.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1990.tb02460.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000235301"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(78)90113-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70506-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1998.00425.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306033282204"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1991.tb03198.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.105706"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1997.tb00996.x"},{"key":"e_1_2_6_16_2","first-page":"345","article-title":"Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1\u2010receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergic effects","volume":"50","author":"Kreutner W","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_17_2","first-page":"S279","article-title":"Functional characterization of desloratadine and other antihistamines in human H1\u2010receptors","volume":"55","author":"Anthes JC","year":"2000","journal-title":"Allergy"},{"key":"e_1_2_6_18_2","first-page":"S278","article-title":"Preclinical studies of desloratadine, a non\u2010sedating, selective histamine H1\u2010receptor antagonist with antiallergic activity","volume":"55","author":"Kreutner W","year":"2000","journal-title":"Allergy"},{"key":"e_1_2_6_19_2","first-page":"S278","article-title":"Desloratadine: cardiovascular, central nervous system, renal and gastrointestinal safety profile of this nonsedating H1 antihistamine","volume":"55","author":"Hey JA","year":"2000","journal-title":"Allergy"},{"key":"e_1_2_6_20_2","first-page":"S277","article-title":"Desloratadine and alcohol co\u2010administration: no increase in impairment of performance over that induced by alcohol alone","volume":"55","author":"Rikken G","year":"2000","journal-title":"Allergy"},{"key":"e_1_2_6_21_2","unstructured":"VuurmanEFPM RamaekersJG RikkenG&De HalleuxF.Desloratadine does not impair actual driving performance: a 3\u2010way crossover comparison with diphenhydramine and placebo.Allergy2000;55 Suppl 63(Abstract 945)."},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90359-X"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb00745.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","unstructured":"SchroederJT SchleimerRP LichtensteinLM&KreutnerW.Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine.Clin Exp Allergy2001(in press).","DOI":"10.1046\/j.1365-2222.2001.01130.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2000.009002118.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.1995.tb00257.x"},{"key":"e_1_2_6_27_2","unstructured":"LebelB BousquetJ CzarlewskiW&CampbellAM.Loratadine reduces RANTES release by an epithelial cell line.J Allergy Clin Immunol1997;99 S444(Abstract 1802)."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1997.tb01154.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1995.tb01133.x"},{"key":"e_1_2_6_30_2","unstructured":"AgrawalDK BerroA&TownleyRG.Desloratadine attenuation of eosinophil chemotaxis adhesion and superoxide generation.Allergy2000;55 Suppl 63:S276(Abstract 990)."}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1398-9995.2001.00104.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1398-9995.2001.00104.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:09:43Z","timestamp":1695744583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1398-9995.2001.00104.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":29,"journal-issue":{"issue":"s65","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1034\/j.1398-9995.2001.00104.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1398-9995.2001.00104.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}